Sol-Gel's rosacea drug clears late-stage hur­dle; uniQure's he­mo­phil­ia gene ther­a­py im­press­es with PhII da­ta

→ Is­rael’s Sol-Gel Tech­nolo­gies‘ mi­croen­cap­su­la­tion plat­form — de­signed to en­trap ac­tive in­gre­di­ents in porous sil­i­ca mi­cro­cap­sules to ad­dress the lim­i­ta­tions of top­i­cal drug de­liv­ery by sta­bi­liz­ing …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER